COR$352.16
$353.74
Chart
Performance
Key Stats
AI COR Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyCencora exhibits strong fundamental performance, particularly in profitability and debt management. While thematic tailwinds are present, current technicals suggest a need for caution due to short-term downward pressure. Suitable for investors seeking stability and consistent income.
Thematic
Cencora operates in the healthcare distribution sector, benefiting from stable demand for pharmaceuticals and medical supplies. Growth is driven by an aging population and increasing healthcare access globally.
Fundamental
Cencora demonstrates robust profitability, a solid balance sheet with manageable debt, and consistent dividend payouts. Revenue growth has been stable, supported by its essential role in the healthcare ecosystem.
Technical
The stock is currently trading below its key moving averages and exhibits bearish momentum. Support levels are being tested, indicating potential for further downside in the short term.
| Factor | Score |
|---|---|
| Healthcare Demand | 85 |
| Supply Chain Efficiency | 75 |
| International Expansion | 60 |
| Regulatory Landscape | 50 |
| Technological Integration | 70 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 70 |
| Growth | 75 |
| Balance Sheet Health | 50 |
| Cash Flow | 80 |
| Dividend Yield | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 45 |
| Volume | 60 |
| Support & Resistance | 50 |
| Moving Averages | 30 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Beat
The company has exceeded earnings per share (EPS) estimates in the last 5 consecutive quarters, demonstrating a strong and consistent ability to deliver on profitability expectations.
Undervalued Relative to Peers
The Price-to-Earnings (P/E) TTM ratio of 33.66 is lower than the industry average of 38.5, suggesting potential undervaluation compared to its peers.
Bearish Points (7)
High P/E Ratio
The TTM Price-to-Earnings (P/E) ratio of 33.66 suggests that investors are paying a premium for the company's earnings, which could lead to volatility if growth expectations are not met.
Slightly Decelerating Revenue Growth
While revenue for fiscal year 2024 (TTM) was $235.99B, the year-over-year growth rate for the latest reported quarter (2024Q1) was 0.6%, indicating a potential deceleration in top-line growth compared to historical trends.
Calendar
May 2025
16
Ex-Dividend Date
June 2025
2
Next Dividend Date
August 2025
6
Next Earnings Date
H: $3.98
A: $3.82
L: $3.65
H: 82.50B
A: 80.29B
L: 78.55B
Profile
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Seasonals
Price Target
324.30 USD
The 39 analysts offering 1 year price forecasts for COR have a max estimate of 355.00 and a min estimate of 257.45.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Provides ubiquitous enterprise software, cloud computing (Azure), and operating systems that form the backbone of global digital operations and business infrastructure.
Weight: 97
Amazon Web Services (AWS) is a leading global cloud computing infrastructure provider, essential for countless businesses and digital services worldwide, alongside its foundational e-commerce logistics.
Weight: 95
Operates Google Cloud, a major cloud computing platform, and provides essential digital infrastructure through its search engine, advertising platforms, and Android mobile OS, fundamental to the digital economy.
Weight: 93
Global leader in communications real estate, owning and operating critical infrastructure like cell towers and data centers, essential for wireless and digital connectivity.